4D Molecular Therapeutics, Inc. (FDMT)
NASDAQ: FDMT · Real-Time Price · USD
3.305
-0.035 (-1.05%)
Apr 29, 2025, 11:53 AM EDT - Market open
4D Molecular Therapeutics Employees
4D Molecular Therapeutics had 227 employees as of December 31, 2024. The number of employees increased by 80 or 54.42% compared to the previous year.
Employees
227
Change (1Y)
80
Growth (1Y)
54.42%
Revenue / Employee
$163
Profits / Employee
-$708,670
Market Cap
153.03M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 227 | 80 | 54.42% |
| Dec 31, 2023 | 147 | 7 | 5.00% |
| Dec 31, 2022 | 140 | 16 | 12.90% |
| Dec 31, 2021 | 124 | 41 | 49.40% |
| Dec 31, 2020 | 83 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
FDMT News
- 17 days ago - 4DMT Announces New Employment Inducement Grants - GlobeNewsWire
- 4 weeks ago - 4DMT to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 7 weeks ago - 4DMT Announces First Patients Enrolled in 4FRONT-1 Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMD - GlobeNewsWire
- 2 months ago - 4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones - GlobeNewsWire
- 2 months ago - 4D Molecular Therapeutics: A Smart Bet On Long-Term VEGF Suppression - Seeking Alpha
- 2 months ago - Eye Disease Focused 4D Molecular Therapeutics Lays Out 52-Week Results From Wet AMD Study - Benzinga
- 2 months ago - 4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration Program - GlobeNewsWire
- 5 months ago - 4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones - GlobeNewsWire